vkarimni@bidmc.harvard.edu
Wed, 28 May 2025 19:05:58 +0000

New advances in miRNA biomarker research, powered by BIDMC's Detection Unit vkarimni@bidmc… Wed, 05/28/2025 - 15:05

Two new studies, presented at HiRM and AACR, identified promising RNA biomarkers in breast cancer and Hodgkin lymphoma. At the heart of both efforts was the Detection Unit at BIDMC’s Precision RNA Medicine Core.

What made these discoveries possible?

High-throughput miRNA screening using Mirxes qPCR panels, quantifying up to 372 miRNAs per sample with precision and sensitivity.

Expert bioanalysis to uncover miRNA candidates with clinical or therapeutic relevance.

Whether you're exploring plasma RNA, working on early detection assays, or validating liquid biopsy markers, this is the core that can help translate your hypothesis into publishable data.

Learn more about the Detection Unit’s services

Explore all BIDMC Omics Core offerings

Read the featured study posters:

•Plasma miR-362-3p and Cisplatin Response in BRCA-Related Breast Cancer (HiRM)

•EBV microRNAs and Hodgkin Lymphoma Prognosis (AACR)

Wednesday, May 21, 2025, 12:00pm